Aug 13, 2026·Score 75·Type A — Value-style analysisUsed for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety.Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology →$543.13
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses.$480.00($460.00–$500.00)
Price TargetOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology →$558.36
Expected Return
Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Type A - Chemed Corporation (CHE) 20260813 Stock Analysis
📅 Chemed Key Upcoming Events
August 17, 2026Q2 2026 Ex-Dividend Date
Description: The stock begins trading without the value of its newly increased $0.70 quarterly dividend, representing a 17% increase over the prior quarter, which underscores management’s high degree of confidence in the underlying free cash flow generation of the consolidated enterprise.
September 03, 2026Q2 2026 Dividend Payment Date
Description: Cash distribution of the declared $0.70 per share dividend to shareholders of record, marking the 221st consecutive quarterly dividend paid by Chemed in its 55 years as a publicly traded company.
October 27, 2026Q3 2026 Earnings Release (Estimated)
Description: Market participants and activist investors will closely monitor whether the VITAS segment can sustain its elevated 9% admission growth rate and if Roto-Rooter successfully mitigates the structural margin pressures arising from escalating digital marketing and paid lead acquisition costs.
February 24, 2027Q4 2026 Earnings Release (Estimated)
Description: Full-year results will confirm whether the significantly raised $25.00 to $25.75 adjusted EPS guidance was successfully achieved, and whether the Florida Medicare Cap cushion remains robust against shifting acuity mixes.
🏢 Step 1: Chemed Company Overview & Business Model
Q1-A1. What is Chemed?
Company Name (Ticker): Chemed Corporation (CHE)
Sector: Healthcare
Exchange: NYSE
Founded: March 01, 1970
Listing Date: May 14, 1982
Fiscal Year End: December
Headquarters: United States, Cincinnati
CEO: Kevin J. McNamara
Market Cap: $7.13B
Shares Outstanding: 13.07M
Current Stock Price:$543.13
Annual Dividend Yield:0.52%
Ex-dividend Date: August 17, 2026 (ET)
As-of: August 13, 2026 (ET)
Q1-A2. How Does Chemed Make Money?
Description: Chemed operates as a highly diversified holding company that manages two entirely distinct, wholly-owned subsidiaries with no operational overlap: VITAS Healthcare and Roto-Rooter. VITAS generates revenue by providing comprehensive end-of-life hospice and palliative care to patients with terminal illnesses. It bills the Medicare and Medicaid programs on a prospective payment system based on daily census volumes across four levels of care: Routine Home Care, Continuous Home Care, Inpatient Respite Care, and General Inpatient Care. Conversely, Roto-Rooter generates revenue by offering residential and commercial plumbing, drain cleaning, and water restoration services. Roto-Rooter monetizes acute, emergency infrastructure failures, charging customers directly for dispatch repair work through a vast network of company-owned branches, independent contractors, and franchised territories across North America.
Q1-A3. Chemed’s Revenue Segments & Core Income Sources
VITAS Healthcare (65.8% of Total Revenue): Generated $443.3 million in net patient revenue during Q2 2026, marking a robust 11.9% year-over-year expansion. This segment serves as the primary demographic growth engine for the enterprise, driven recently by a 6.1% increase in Average Daily Census (ADC) to 23,687 patients and a massive 9.0% rise in hospital-based admissions. The segment produces immense cash flow, yielding an adjusted EBITDA of $80.6 million at an 18.2% margin.
Roto-Rooter (34.2% of Total Revenue): Generated $229.9 million in Q2 2026 revenue, growing at a more mature 3.3% year-over-year rate. It functions as the enterprise’s high-margin, recession-resistant cash cow, posting an adjusted EBITDA of $48.5 million. However, the segment’s profitability profile has recently encountered friction; its 21.1% EBITDA margin represents a 77-basis point year-over-year decline, fundamentally pressured by structural increases in digital marketing expenses as paid internet search leads rose from 44% to 59% of total leads over the past 18 months.
Q1-A4. Who Are Chemed’s Competitors?
VITAS Competitors: The hospice segment competes directly with large, publicly traded post-acute care and home health providers such as Amedisys, Encompass Health, and Addus HomeCare, alongside thousands of highly fragmented, localized, independent hospice agencies. VITAS defends its market share through unrivaled scale as the nation’s largest for-profit hospice provider and relies heavily on deep, entrenched referral networks with major hospital systems. Furthermore, its dominance is structurally protected in certain states by Certificate of Need (CON) regulations that erect steep bureaucratic barriers against new market entrants.
Roto-Rooter Competitors: The plumbing and drain cleaning segment competes primarily with highly fragmented local “mom-and-pop” plumbing contractors, as well as national franchise operators such as Mr. Rooter, HomeServe, and private-equity-backed home service platforms. Roto-Rooter secures its dominant industry position through unmatched national brand equity, massive advertising budgets, and extreme route density, which allows for rapid emergency dispatch logistics that smaller competitors simply cannot replicate.
Q1-A5. Chemed Key Events: Past 12 Months
October 28, 2025Q3 2025 Earnings Release
Description: The company reported earnings of $5.27 per share, missing the analyst consensus estimate of $5.36 by $0.09, which temporarily pressured the stock as the market digested near-term margin constraints at Roto-Rooter and Medicare Cap concerns.
February 25, 2026Q4 2025 Earnings Release
Description: Chemed reported a significant earnings miss of $0.65 per share below the $7.07 estimate. The shortfall was heavily influenced by a severe $16.4 million Medicare Cap billing limitation charge in the prior year compounding into conservative forward guidance, overshadowing underlying patient volume stability.
March 31, 2026Acquisition of San Francisco and Fort Worth franchises
Description: Roto-Rooter executed a strategic tuck-in acquisition, purchasing independent franchise territories in California and Texas for a combined $20.6 million. This accretive move is anticipated to add up to $5.5 million in high-margin, company-owned annual revenue, demonstrating the viability of the internal franchise roll-up strategy.
April 01, 2026Entry into a new $450 million revolving credit facility
Description: Chemed fortified its balance sheet by entering a new five-year Amended and Restated Credit Agreement, featuring a $450 million revolving line of credit and a $250 million expansion feature. This facility provides vast liquidity to sustain the company’s aggressive share repurchase cadence and localized M&A strategy without stressing operating cash flow.
April 23, 2026Q1 2026 Earnings Release
Description: The company delivered an operational turnaround, posting an EPS beat of $0.12 above consensus ($5.63 vs $5.51) and raising its full-year guidance on the back of resilient hospice admissions, sparking a sustained recovery in the stock price.
June 03, 2026Activist investor Barington Capital accumulates a stake
Description: Activist fund Barington Capital, led by James Mitarotonda, publicly revealed an equity stake in Chemed, criticizing the board for a lack of ambition and accountability. Barington demanded an immediate strategic review, the curtailment of executive perks (such as the CEO’s personal aircraft use), and the addition of Chan Galbato to the board, raising the ultimate specter of a corporate spin-off to unlock the conglomerate discount.
June 08, 2026Acquisition of South Texas Roto-Rooter franchises
Description: Roto-Rooter further expanded its company-owned footprint by purchasing a franchise territory spanning 21 counties in South Texas, including Corpus Christi, for approximately $12.0 million. Management noted this represents a long-term growth opportunity for 2027 and beyond.
July 28, 2026Q2 2026 Earnings Release
Description: Chemed delivered a massive financial beat, reporting adjusted EPS of $6.06 against estimates of $5.60, alongside an 8.8% year-over-year revenue increase to $673.3 million. Driven by explosive 11.9% net patient revenue growth at VITAS and a drastic reduction in Medicare Cap limitations, management aggressively raised the full-year 2026 adjusted EPS guidance from a prior $24.00–$24.75 range to $25.00–$25.75.
July 30, 2026CMS finalizes FY 2027 Hospice Wage Index and Payment Rate Update
Description: The Centers for Medicare & Medicaid Services (CMS) officially enacted a 2.3% rate increase for hospice providers, adding roughly $755 million in aggregate national payments while establishing the FY 2027 aggregate hospice payment cap at $36,174.75. The rule also introduced the Service and Spending Variation Index (SSVI) to increase program transparency and target non-compliant billing outliers.
Q1-A6. Step 1 Key Takeaways
Step 1 Summary: Chemed operates a highly unusual, dual-engine conglomerate business model where the accelerating, demographically supported growth of the VITAS hospice segment is counterbalanced by the mature, recession-resistant cash generation of the Roto-Rooter plumbing segment, fueling a relentless capital return program.
Top 3 Red Flags:
1 Structural margin compression at Roto-Rooter, heavily driven by the permanent inflation of digital marketing acquisition costs as paid search leads ballooned from 44% to 59% of total intake over the last 18 months.
2 Escalating activist pressure from Barington Capital, which has publicly attacked the board’s complacency, executive perks, and the inefficient conglomerate structure, demanding immediate strategic reviews.
3 Persistent regulatory vulnerability to the CMS Medicare Cap, which dictates stringent billing limitations in high-volume, long-duration patient geographies like Florida.
Top 5 Key Financial/Operational Indicators for Next-Level Analysis:
1 VITAS Average Daily Census (ADC) and hospital-based admission growth trajectories.
2 Roto-Rooter Adjusted EBITDA margin stabilization against paid lead costs.
3 Trailing 12-month share repurchase volumes and remaining capital authorization limits.
4 The frequency and severity of CMS Medicare Cap billing limitation accruals.
5 Corporate free cash flow conversion rates across both disparate segments.
Top 3 Unconfirmed and Estimated:
1 ➖ Not applicable.
🏰 Step 2: Chemed’s Economic Moat, Growth & Capital Allocation
Q2-A1. Does Chemed Have a Durable Economic Moat?
Entry barriers: VITAS possesses a moderate-to-wide moat fundamentally anchored by stringent regulatory barriers. In highly populated states such as Florida, Certificate of Need (CON) laws severely restrict the issuance of new hospice licenses, artificially capping competition and protecting entrenched incumbents from new entrants. Meanwhile, Roto-Rooter operates with robust intangible asset advantages via unrivaled national brand recognition, augmented by the sheer, insurmountable route density required to execute rapid-response emergency dispatch logistics efficiently, creating a formidable barrier against localized competitors.
Pricing power: The enterprise exhibits a stark dichotomy in pricing autonomy. Roto-Rooter demonstrates robust, inflationary-resistant pricing power characteristic of emergency services; both residential and commercial clients are highly price-inelastic when facing acute plumbing failures or water damage. Conversely, VITAS possesses zero direct pricing power, as its reimbursement rates are unilaterally dictated by CMS, which recently capped the FY 2027 Hospice Wage Index update at a modest 2.3% despite pervasive nursing wage inflation.
Profitability defense: The company consistently generates a massive Return on Invested Capital (ROIC) exceeding 27%, underscoring the structural durability of its asset-light operations. Even with zero pricing power in the healthcare segment and escalating lead generation costs in the plumbing segment, the combined entity protects its profitability through aggressive volume scaling and ruthless corporate cost control.
Q2-A2. Is Chemed’s Growth Sustainable?
Industry structure and outlook: The hospice industry is riding an irreversible structural tailwind: the rapid aging of the U.S. demographic. The total addressable market (TAM) for end-of-life palliative care expands mechanically year over year. Simultaneously, the emergency plumbing sector remains a mature, highly resilient necessity market that performs consistently across all macroeconomic environments.
Growth sustainability: Growth is highly sustainable and structural in nature, driven by baseline human morbidity and infrastructure decay rather than cyclical discretionary spending. However, the sustainability of the current growth rate could be halted under three specific downside scenarios:
1 Severe, unilateral legislative cuts to Medicare hospice reimbursement rates by a cost-conscious Congress aiming to curb soaring federal healthcare deficits.
2 A permanent, structural shift in digital advertising algorithms (particularly Google Local Services) that permanently degrades Roto-Rooter’s customer acquisition cost metrics beyond the point of operational viability.
3 Escalating national deficits of licensed master plumbers and registered nurses that aggressively compress operating margins faster than Roto-Rooter can raise prices or VITAS can absorb through volume.
Q2-A3. How Does Chemed Allocate Capital & Return Cash?
Priorities and consistency: Chemed executes a masterclass in disciplined, shareholder-friendly capital allocation, heavily skewed toward aggressive and continuous share repurchases. Over the trailing 12 months ending June 30, 2026, the company deployed massive cash reserves to repurchase 1.51 million shares at an average price of $423.63, effectively contracting the outstanding share count by a staggering 10.5%.
Reinvestment and acquisitions: Excess capital not utilized for repurchases is intelligently directed toward highly accretive, low-risk tuck-in acquisitions. The company actively purchases independent Roto-Rooter franchise territories (such as the recent $20.6M and $12M acquisitions in Texas and California) to seamlessly consolidate margins under company-owned operations.
Dividend strategy: Management recently hiked the quarterly dividend by 17% to $0.70 per share. While the absolute 0.52% yield appears modest, it marks the 221st consecutive quarterly payout, reinforcing an immaculate track record of steady, conservative cash returns layered atop the massive buyback program.
Q2-A4. Step 2 Key Takeaways
Scoring Rationale:
Economic Moat (8/10): The company commands strong regulatory and brand-driven moats, though the score is slightly capped because VITAS remains entirely dependent on government-dictated pricing updates.
Growth Sustainability (6/8): Solid demographic tailwinds support volume growth, but structural digital marketing cost inflation at Roto-Rooter severely limits near-term margin expansion.
Capital Allocation (7/7): Flawless execution of highly accretive share repurchases, retiring 10.5% of the float while simultaneously hiking the dividend and acquiring high-margin franchise territories.
Step 2 Summary: Chemed operates with highly defensible competitive positions in both subsidiaries, supported by robust demographic demand and an exceptional, hyper-efficient capital allocation engine that structurally enhances per-share value independent of market cycles.
💰 Step 3: Is Chemed Profitable? Financial Health Analysis
Q3-A1. Chemed’s Growth & Profitability Trends
Analysis of growth and revenue indicators: Over the past five years, revenue expanded steadily from $2.13 billion to $2.53 billion in 2025, with net income consistently stabilizing near $265 million. Q2 2026 emphatically accelerated this operational strength, with consolidated revenue rising 8.8% year-over-year to $673.3 million, and adjusted EPS surging a massive 41.9% to $6.06.
Profitability margin and leverage verification: Operating margins expanded significantly in Q2 2026, rising to 13.2% from 11.0% the prior year. This confirms a profound ‘operating leverage’ effect, as accelerated hospital-based VITAS admissions efficiently absorbed fixed back-office costs, which management intentionally engineers to grow at half the rate of topline revenue.
Q3-A2. How Profitable Is Chemed? (Margins & ROIC)
ROIC and value-added assessment: Chemed produces exceptional profitability with a normalized ROIC of 27.29%, Return on Assets (ROA) of 20.21%, and a Return on Equity (ROE) of 32.84%. This overwhelmingly exceeds any reasonable estimation of its weighted average cost of capital (WACC, typically 7-9% for mature healthcare/service firms), indicating massive intrinsic economic value creation over the past cycle.
Industry comparison: The asset-light nature of both hospice care and dispatch plumbing allows Chemed to generate outsized returns on minimal tangible capital compared to capital-intensive peers like Tenet Healthcare or traditional asset-heavy facility operators.
Q3-A3. What Drives Chemed’s Returns? (ROIC Breakdown)
Industry-specific efficiency analysis: Chemed’s phenomenal ROIC is fundamentally driven by extraordinarily high capital velocity and asset turnover. The enterprise boasts an asset turnover ratio of 1.57x, well above the 1.35x healthcare industry average, as neither VITAS nor Roto-Rooter requires heavy manufacturing equipment, extensive physical plant infrastructure, or large inventory bases.
Capacity and network utilization: The primary efficiency driver for VITAS is Average Daily Census (ADC) optimization against fixed nursing staff costs. For Roto-Rooter, efficiency hinges entirely on route density optimization and the conversion rate of paid digital leads into high-ticket commercial plumbing contracts.
Q3-A4. Are Chemed’s Earnings High Quality?
Checking the quality of profits: Earnings quality is immaculate. The consolidated business routinely generates operating cash flow that far exceeds its reported net income due to favorable working capital dynamics and non-cash depreciation add-backs. In Q2 2026 alone, cash flow from operations exceeded $173 million against a net income of $67.7 million, proving the profits are backed by hard cash rather than accounting accruals.
Cash flow conversion: The historical Price-to-Cash-Flow ratio trades near 19x-22x. The company routinely utilizes this massive free cash flow conversion to fund unconstrained, self-sustaining share repurchases without ever relying on external equity financing.
Q3-A5. Is Chemed’s Balance Sheet Healthy? (Debt & Leverage)
Leverage adequacy analysis: The balance sheet is extraordinarily pristine. As of mid-2026, Chemed carries a trivial $140.0 million in long-term debt against a $7.13 billion market capitalization. The Debt-to-Equity ratio sits at an ultra-conservative 0.17 to 0.29.
Liquidity and refinancing risk assessment: Short-term liquidity is adequate, with a quick ratio measuring 0.72 and a current ratio of 0.91. While optically below 1.0, this is perfectly normal and highly secure given the extremely predictable, rapid daily cash inflows characteristic of the direct-service model.
Interest repayment ability verification: The interest coverage ratio stands at a staggering 111.99x. This indicates that operating profits can cover debt obligations effortlessly over one hundred times over, virtually eliminating any possibility of insolvency or refinancing risk.
Q3-A6. Step 3 Key Takeaways
Scoring Rationale:
Profitability·Capital Efficiency (9/10): Exceptional ROIC exceeding 27% and strong operating leverage generated by accelerated hospice patient volumes.
Cash Flow·Profit Quality (7/8): Operating cash flow consistently and vastly exceeds net income, demonstrating flawless, high-quality earnings conversion.
Financial Soundness·Debt Management (7/7): Near-zero net debt risk with a massive 111x interest coverage ratio providing total capital flexibility.
Step 3 Summary: Chemed operates an elite, asset-light financial engine that prints free cash flow with minimal debt, allowing unhindered, perpetual deployment of capital into repurchases, dividends, and bolt-on acquisitions.
Evidence: Historic issues regarding aggressive hospice billing and false claims for continuous home care were fully resolved via a massive $75 million DOJ settlement in 2017. Operations are now heavily governed by a strict Corporate Integrity Agreement (CIA), which has normalized compliance and eliminated aggressive revenue recognition tactics.
Cost capitalization: not found
Evidence: Financial filings reveal no irregular capitalization of routine plumbing or nursing expenses; costs are expensed cleanly through the income statement.
Sharp increase in accounts receivable and inventory: not found
Evidence: Asset turnover remains highly stable, and accounts receivable align naturally with the 8.8% consolidated revenue growth reported in Q2 2026.
Non-recurring adjustment (normalization): not found
Evidence: Adjustments bridging GAAP EPS ($5.13) and non-GAAP Adjusted EPS ($6.06) are transparently attributed to standard, easily verifiable stock-based compensation and discrete tax/litigation items, entirely consistent with long-standing historical reporting practices.
Q4-A2. Is Chemed Overspending? (Capex & Capital Cycle)
➖ Not applicable: The capital-cycle and oversupply lens does not apply directly to Chemed’s asset-light service structure, as growth is dictated by labor procurement and localized demographic demand rather than the construction of heavy manufacturing or capacity-based infrastructure.
Q4-A3. How Sound Is Chemed’s Cash Flow?
Checking the quality of profits: Operating cash flow robustly tracks and often heavily exceeds net income due to the non-cash nature of depreciation, amortization, and stock-based compensation. This completely negates any risk of fictitious book earnings inflating the bottom line.
Cash flow stability and dependence: Cash is organically generated strictly through core service operations. The business does not rely on equity issuances or debt raises to fund its working capital; rather, it actively uses its massive cash surplus to retire its own shares.
Q4-A4. Is Chemed Diluting Shareholders?
⏪ Confirmed (Past) Dilution: There is absolute zero dilution; the company has engineered a masterclass in equity contraction. By aggressively repurchasing 1.51 million shares over the trailing 12 months, Chemed has reduced its outstanding share base by roughly 10.5%, massively concentrating the EPS profile for remaining shareholders.
⏩ Potential (Future) Dilution & Overhang: Ongoing accretion is the definitive path forward. The company maintains an outstanding share repurchase authorization of $139.8 million as of June 30, 2026, signaling that management fully intends to continue destroying shares on the open market.
Number of shares: Diluted weighted average (13.19M) unified ➡ (Pass)
Unit: USD / Millions unified ➡ (Pass)
Single Value Confirmation: Core financial figures cross-validated seamlessly across official SEC disclosures and platform screeners ➡ (Pass)
Q4-A6. Step 4 Key Takeaways
Scoring Rationale:
Accounting anomalies·distortion signals (8/8): Post-2017 compliance regimes are strictly adhered to, with transparent GAAP to non-GAAP bridges.
Cash flow warning signals (7/7): Phenomenal organic cash conversion requires zero external financing to run daily operations.
Dilution factors (5/5): Management is conducting a masterclass in anti-dilution, actively retiring an incredible 10.5% of the total float in a single year.
Step 4 Summary: Chemed’s financial statements are pristine, entirely free from aggressive accounting maneuvers, and driven by a structural cash-generating mechanism that overwhelmingly benefits existing shareholders through extreme equity contraction.
Q5-A1. Can You Trust Chemed’s Management? (Guidance Track Record)
Guidance Hit Rate: Exceptional. Management has established a long-standing history of conservative forecasting, regularly beating quarterly Wall Street consensus estimates. Following a blowout Q2 2026, the company raised full-year adjusted EPS guidance substantially from $24.00–$24.75 to $25.00–$25.75, validating management’s deep operational visibility and execution capabilities.
Transparency and Consistency Between Words and Actions: Executive communication is highly pragmatic and grounded. Management openly acknowledged the severe margin headwinds caused by structural digital marketing costs at Roto-Rooter, rather than attempting to obscure this negative data beneath the extraordinarily strong VITAS hospice performance.
Q5-A2. What Are Chemed Insiders Doing?
Insider Trading Status and Context Analysis: Recent insider activity leans notably bearish from a signaling perspective. In early August 2026, CEO Kevin McNamara executed a significant sale of roughly $1.1 million in stock on the open market at approximately $540 per share following an options exercise. This was preceded by another director, Patrick Grace, selling $101,080 worth of shares. While entirely typical for executives managing long-term, stock-based compensation, the complete lack of open-market cluster buying near 52-week highs indicates that management views the current valuation as fully priced.
Evaluating executive confidence signals: There are no open market cluster buys to speak of; standard liquidity events dominate recent Form 4 filings, providing no actionable bullish sentiment from internal leaders.
Q5-A3. Is Chemed’s Management Aligned With Shareholders?
Voting Rights and Governance Check: The company operates under a standard single-class voting structure, offering proportional rights to common shareholders without differential voting distortions. However, governance is currently under severe public assault. Activist investor Barington Capital has publicly criticized the board for a lack of ambition, weak accountability, and excessive executive perks (specifically highlighting the CEO’s personal use of corporate aircraft and sporting event tickets), pushing for immediate strategic reviews and board refreshment.
Incentive alignment assessment: While long-term incentive compensation successfully tracks share price appreciation (evident in the massive, sustained multi-year buyback programs that boost EPS), the activist friction indicates that legacy governance frameworks may be overly accommodating to entrenched leadership, necessitating external pressure to maximize shareholder value.
Q5-A4. Step 5 Key Takeaways
Scoring Rationale:
Management Trust (4/5): Guidance reliability is excellent and transparent, though Roto-Rooter margin headwinds remain unresolved.
Insider Trends (3/5): CEO and director sales near 52-week highs present a mildly cautious signal, offset only by the company’s buybacks.
Governance·Compensation System (3/5): Activist campaigns targeting board complacency and exorbitant executive perks drag down the governance score.
Step 5 Summary: While operational execution remains top-tier, recent insider selling and mounting activist pressure over governance structures and capital efficiency suggest leadership alignment is facing a necessary, forced modernization.
⛵ Step 6: Chemed Market Flow & Sentiment
Q6-A1. Analyst Consensus vs Chemed Guidance
Guidance gap and direction analysis: Following Q2 2026, management raised the FY 2026 EPS guidance midpoint to $25.38. Meanwhile, the analyst consensus has historically lagged reality, with an average price target hovering around $530.75, trailing behind the current $543.13 trading price. This gap indicates that sell-side analysts are overly conservative compared to the company’s own internal trajectory, largely due to lingering fears over Medicare Caps.
Tracking recent sentiment changes: Sentiment is gradually shifting bullish post-Q2. Institutions like Oppenheimer aggressively raised price targets to $590 with Outperform ratings, recognizing the durability of the hospice admission rebound, while others maintain a cautious Hold posture.
Q6-A2. What Is Chemed’s Short Interest?
Institutional Trends: The stock enjoys massive institutional support, with heavyweights holding over 95% of the total float, thereby limiting retail-driven volatility and anchoring the technical price floor.
Short Selling Indicators: Short interest is noticeably elevated at approximately 12.0% of the float, with roughly 4.7 days-to-cover. This significant short positioning suggests that a concentrated cohort of speculative traders is betting heavily against the company’s premium valuation multiple, or anticipating imminent structural margin erosion within the plumbing division due to lead cost inflation.
Q6-A3. Step 6 Key Takeaways
Scoring Rationale:
Consensus vs Guidance (2/3): The company is outpacing sluggish sell-side estimates, forcing gradual upward revisions.
Supply·Short Interest (1/2): Elevated 12% short interest creates technical friction and indicates real skepticism, despite solid long-only institutional ownership.
Step 6 Summary: Market sentiment is mixed; robust earnings momentum is actively battling cautious analyst targets and a stubbornly high short-seller presence.
🚀 Step 7: Chemed Catalysts & Price Triggers
Q7-A1. What Could Move Chemed Stock? (Top 3 Catalysts)
1 Barington Capital Activist Campaign and Potential Spin-off
Timing: Next 6-12 months
Success Conditions: Barington successfully pressures the board into initiating a formal strategic review that culminates in the spin-off of the Roto-Rooter division. This action eliminates the conglomerate discount and unlocks standalone multiples, allowing pure-play healthcare and industrial service investors to price the assets higher independently.
Failure Risk: Management firmly entrenches itself, rejecting the spin-off due to massive frictional tax liabilities, causing arbitrageurs and activist funds to exit the stock in frustration.
2 Stabilization of Roto-Rooter Digital Acquisition Costs
Timing: Next 3-6 months
Success Conditions: The plumbing segment successfully offsets escalating Google Local Services lead costs by accelerating the closure rate of high-margin commercial/B2B contracts, restoring the EBITDA margin to its historical 23% benchmark.
Failure Risk: Digital marketing inflation proves structural and irreversible, permanently compressing plumbing margins and eroding the cash flow traditionally used to fund the buyback engine.
3 Aggressive Acceleration of Franchise Buybacks
Timing: Next 6-12 months
Success Conditions: Management deploys its expanded $450 million credit facility to aggressively acquire highly profitable, independent Roto-Rooter territories (similar to the recent Texas and California deals), driving immediate EPS accretion by eliminating franchise-fee friction.
Failure Risk: Acquisition targets demand excessive multiples, limiting capital deployment opportunities and stalling inorganic growth.
Q7-A2. Chemed’s Earnings Revision Trend
Tracking EPS estimate changes: Earnings revisions are decisively positive. The massive $0.46 Q2 EPS beat has forced a complete reset of forward expectations, with management lifting the full-year EPS floor from $24.00 to $25.00 and the ceiling to $25.75. This fundamental outperformance has catalyzed near-term multiple expansion, as analysts scramble to adjust their models to reflect the surging VITAS Average Daily Census volumes.
Q7-A3. Step 7 Key Takeaways
Scoring Rationale:
Catalyst (6/7): The activist-driven spin-off narrative introduces a highly potent, actionable catalyst capable of unlocking massive conglomerate value.
EPS Trend (3/3): Definitive upward revisions following a flawless Q2 operational beat and a raised internal guidance floor.
Step 7 Summary: The combination of an escalating activist campaign and continuous upward earnings revisions provides a powerful fundamental floor and significant event-driven upside.
⚖️ Step 8: Is Chemed Fairly Valued? Valuation Analysis
P/E Ratio (Trailing 12 Months): 27.2x (overvalued)
P/E Ratio (Forward): 21.2x (overvalued)
PEG Ratio: 2.09 (overvalued)
Price to Sales Ratio: 2.8x (fairly valued)
Price to Book Ratio: 8.7x (overvalued)
Price to Cash Flow Ratio: 22.4x (overvalued)
EV/EBITDA Ratio: 15.2x (overvalued)
Scoring Rationale: Across almost all absolute multiple lenses—particularly a trailing P/E above 27x, a Forward P/E over 21x, and an EV/EBITDA over 15x—the stock screens as expensive relative to the broader market, demanding premium execution to justify the heavy price tag.
📌 (1) Axis Q8-A1 Score:-2
Q8-A2. Chemed vs Peers: Valuation Comparison
Multiple selection based on peer comparison: Forward PER
Calculation of peer-to-peer deviation rate: +30.0%
Scoring Rationale: Compared to its closest post-acute home care peer, Addus HomeCare, which trades near a 16.3x forward P/E, Chemed’s 21.2x multiple commands a stark premium. While its dual-monopoly structure and massive buybacks justify some elevation, a 30% gap borders on the very overvalued boundary relative to pure-play healthcare peers.
📌 (2) Axis Q8-A2 Score:-2
Q8-A3. Is Chemed Cheap or Expensive vs Its History?
Comparison Indicators: Trailing P/E
Scoring Rationale: Chemed’s 5-year historical average P/E sits at 28.1x. The current 27.2x trailing P/E places it comfortably near the midpoint of its historical band (Top 40-60%), indicating it is trading exactly in line with the market’s traditional historical valuation of the asset.
📌 (3) Axis Q8-A3 Score:0
Q8-A4. What Growth Is Priced Into Chemed? (Reverse DCF)
Implied Growth Rate:9.8%
1 Methodology: PEG-based inversion
2 Core assumptions: Current 21.2x Forward P/E against a historical market PEG baseline of roughly 2.0x to 2.1x implies the market demands near double-digit sustained earnings growth to maintain the current multiple.
Achievable Growth Rate:11.5%
Basis: Management’s raised EPS guidance midpoint ($25.38) reflects roughly a 13-17% jump over prior years, with the forward long-term trajectory realistically pegged at low double digits via steady repurchases and census growth.
Scoring Rationale: The market’s embedded growth expectations closely match the company’s highly reliable, share-repurchase-driven earnings cadence, indicating a fair valuation where growth demands are perfectly rational and attainable.
📌 (4) Axis Q8-A4 Score:0
Q8-A4-1. What Growth Hurdle Does the Market Demand From Chemed? (Reverse DCF Alternative)
(3) Axis Q8-A3 (Historical Band Position): Fairly Valued
(4) Axis Q8-A4 (Justification for Growth): Fairly Valued
The valuation axes produce a 2:2 split between overvalued and fairly valued, lacking a clear 3-axis majority consensus. This triggers the mechanical conservative penalty to account for the conflicting logics.
📌 (5) Axis Q8-A5 Score:-2
Q8-A6. Chemed’s Hidden Asset & Stake Valuation
➖ Not applicable: (Not applicable)
📌 (6) Axis Q8-A6 Score:➖
Q8-A7. Final Valuation Adjustment
Scoring Rationale: A one-point positive adjustment is applied because the company is actively targeted by an activist investor pushing to eliminate the conglomerate discount via a spin-off of the Roto-Rooter division. This structurally establishes a sum-of-the-parts “floor” on the valuation, artificially de-risking the high multiples.
Commentary: The company screens as mildly overvalued on an absolute basis, but aggressive capital returns, exceptional ROIC, and activist involvement act as a powerful counterbalance, preventing extreme downside.
Step 8 Summary: While carrying a premium multiple characteristic of a high-quality compounder, Chemed’s current price appropriately reflects its intrinsic strength without offering a deep discount.
💀 Step 9: What Are the Risks of Chemed? Fatal Risks & Pre-Mortem
Q9-A1. What Are the Biggest Risks to Chemed?
1 Permanent Margin Compression from Digital Lead Acquisition:
Cause: Alphabet’s (Google) algorithms heavily dominate local service advertising, structurally raising the cost-per-click for Roto-Rooter’s emergency dispatches. Paid search leads have ballooned from 44% to 59% of total intake over the last 18 months.
Cause: The federal government continually audits healthcare spending, historically utilizing Medicare Cap billing limitations to claw back excessive hospice profits. The introduction of the Service and Spending Variation Index (SSVI) by CMS increases scrutiny on billing outliers.
Impact: Financial (Top-line revenue stagnation).
Mitigation/Monitoring Indicators: Monitoring the frequency and dollar amount of CMS Medicare Cap billing limitations reported in quarterly filings (currently projected at $7.0 million for 2026).
3 Specialized Labor Shortages:
Cause: An acute national deficit of registered nurses for VITAS and licensed master plumbers for Roto-Rooter creates severe wage inflation.
1 Labor & Wage Inflation (⬇): Because both segments are 100% human-capital intensive, sustained wage inflation directly attacks the gross margin profile before pricing can be adjusted, suppressing enterprise value.
2 Regulatory/Policy Shifts (⬇): Absolute dependency on CMS for VITAS pricing means a stroke-of-the-pen regulatory cut would immediately compress the company’s revenue ceiling.
Q9-A3. Chemed Pre-Mortem: What Could Go Wrong?
1 The Google Tax Erodes the Cash Cow: Roto-Rooter finds itself entirely beholden to digital ad monopolies for customer flow, causing customer acquisition costs to skyrocket past profitability limits and suffocating the buyback engine.
Early Warning Signal: Roto-Rooter’s adjusted EBITDA margins slip structurally below 19% for three consecutive quarters.
Early Warning Signal: Sudden, unexplained departures of division-level executives at VITAS or Roto-Rooter.
3 Medicare Cracks Down on Hospice Duration: Congress, alarmed by ballooning end-of-life care costs, enforces draconian new admission criteria, slashing Average Daily Census volumes across the industry.
Early Warning Signal: CMS introduces massive unexpected cuts to the annual Hospice Wage Index update.
Q9-A4. Risk Adjustment Score
Reason for Scoring: The risks are present and highly visible (particularly marketing cost inflation at Roto-Rooter and Medicare caps), but they are thoroughly quantified by management and have not structurally damaged the company’s immense free cash flow generation. The deduction remains firmly in the controllable psychological concern range.
📊 Risk Adjustment Score:-6 pts
Step 9 Summary: Chemed’s risks are highly localized to specialized labor availability and government reimbursement structures, yet entirely manageable given the company’s exceptional liquidity and scale.
Commentary: The firm’s exceptional moat, flawless cash flow generation, and highly disciplined capital allocation strongly buffer the moderate valuation penalty and manageable regulatory risks, anchoring the systematic score firmly in resilient territory.
Q10-A2. Should You Buy Chemed? (Recommendation)
Recommendation:Hold
Commentary: While operations are thriving and the activist spin-off narrative offers upside, the stock currently trades too near historical highs and premium multiples to aggressively accumulate, demanding a wider margin of safety before initiation.
Q10-A3. Investment Thesis in One Line
Chemed is an elite cash-flow compounder masking a robust hospice growth engine and a resilient plumbing business, trading at a premium valuation that currently limits upside unless an activist-driven spin-off unlocks its conglomerate discount.
Q10-A4. Chemed’s Price Trend & Key Drivers
Stock Price Trends Over the Past 12 Months:Sideways movement ➡️
July 30, 2026CMS Hospice Rate Finalization
Description: CMS finalized a 2.3% rate increase for FY 2027, clearing regulatory overhang and removing fears of draconian cuts to the palliative care model. ➡ Price Stabilization
July 28, 2026Massive Q2 Earnings Beat and Guidance Raise
Description: VITAS hospital admissions accelerated, allowing the company to crush EPS estimates by $0.46 and confidently raise the full-year floor to $25.00. ➡ Stock Price Surge
June 03, 2026Activist Investor Stake Revealed
Description: Barington Capital’s disclosure forced the market to price in a potential sum-of-the-parts revaluation, bringing renewed institutional attention to the stock. ➡ Upward Momentum
Q10-A5. Action Plan
Current Price:$543.13
Buy Zone:$480.00 ($460.00–$500.00)
(1) Calculation of Fundamental Value: To secure a true margin of safety against an elevated 21.2x forward P/E, acquiring shares closer to an 18x multiple on forward EPS represents a mathematically sound entry point, heavily shielding against potential activist failure or plumbing margin decay.
(2) Momentum Premium/Discount Application: Given the high institutional ownership (over 95%) and the steady drumbeat of daily share repurchases retiring 10.5% of the float, the stock holds a robust technical floor; severe discounts are unlikely unless broader market liquidity fails.
(3) Conclusion: The targeted buy zone absorbs the current valuation premium, demanding a pullback to approximately $480.00 to balance the persistent Roto-Rooter margin pressures against the high-quality cash generation of the hospice segment.
Price Target:$558.36
Expected Return:+2.8% (vs. current price)
📍 Select target stock price calculation criteria:
Forward P/E Multiple — Highly reliable for a mature, heavily repurchased service compounder operating in predictable necessity markets.
🧮 Price Target Calculation Formula:
Per share indicator based (Forward PER, P/FCF, etc.): Forward EPS $25.38 × 22.0x = $558.36
Basis for applying the multiple: Historical valuation band — 22.0x — Discounted slightly below the 28x trailing average to conservatively account for the structural inflation in plumbing lead costs.
Conditions and timing for reaching price target:
1 Roto-Rooter margin stabilization in Q3 2026.
2 Formal announcement of a strategic review by the Board of Directors within 6-12 months.
Stop Loss:$430.00 ($420.00–$440.00)
Action trigger upon catalyst achievement:
1 Management announces a formal spin-off of the Roto-Rooter division
Description: The conglomerate discount evaporates, forcing immediate multiple expansion as pure-play peers dictate the new valuation ceiling for both independent entities. 👉 Increased Holdings (Buy)
2 Roto-Rooter EBITDA margins structurally recover to 23%
Description: Operational fears regarding digital lead costs are extinguished, validating the durability of the cash-flow engine. 👉 Wait/Hold
Action trigger upon risk realization:
1 CMS implements severe retroactive Medicare Cap penalties in Florida
Description: A direct hit to current-year free cash flow severely limits the capacity for immediate share repurchases, weakening the technical floor. 👉 Reduction in Holdings (Sell)
Customized Strategy Guide by Investment Preference:
Defensive Investors: Wait for the stock to retreat into the core $480 Buy Zone; rely on the steady $0.70 quarterly dividend and relentless corporate buybacks for downside protection.
Neutral Investors: Maintain current holdings; the asset-light compounding nature of the business easily supports a Hold rating while waiting for activist developments to unfold.
Aggressive Investors: Initiate a tracking position here to capture the event-driven upside of a potential spin-off, adding aggressively on any technical weakness below $520.
🕵️♂️ Deep Dive Analysis
Q1: Is Chemed’s Conglomerate Structure Its Biggest Weakness?
Analysis: Operating a palliative hospice care provider (VITAS) alongside a drain cleaning service (Roto-Rooter) offers zero operational synergies, supply chain overlap, or cross-selling opportunities. The lack of cross-segment efficiencies forces the market to apply a traditional “conglomerate discount” to the stock. Barington Capital’s activist thesis relies entirely on the premise that separating these entities would allow pure-play healthcare and industrial service investors to price the assets higher independently. However, management has historically resisted, utilizing the robust, capital-light cash flow from plumbing to seamlessly fund the aggressive repurchases that drive overall EPS growth across both segments.
Judgment:Neutral — While a spin-off would undoubtedly unlock near-term multiple expansion by eliminating the structural discount, the current structure’s ability to seamlessly channel plumbing cash flow into tax-efficient share repurchases has undeniably compounded long-term shareholder wealth over the past decade.
Q2: Can Chemed’s 27x Trailing P/E Be Justified by the Hospice Growth Rebound?
Analysis: A 27.2x trailing multiple is undeniably steep for a company lacking hyper-growth technology characteristics. However, the multiple is fundamentally supported by two massive counterweights: an elite 32.8% Return on Equity and a management team that aggressively shrinks the denominator (shares outstanding) by 10.5% annually. Furthermore, as VITAS hospital admissions accelerated by an astonishing 9.0% in Q2 2026, driving an 11.9% net patient revenue increase, the organic growth engine proved it possesses the velocity required to compress that forward multiple rapidly.
Judgment:Fairly Valued — The elevated trailing multiple accurately reflects the premium investors are willing to pay for a dominant, asset-light operator that continually beats conservative guidance while returning massive amounts of capital to shareholders.
Q3: Will Roto-Rooter’s Rising Digital Acquisition Costs Permanently Erode Margins?
Analysis: Roto-Rooter’s Q2 2026 adjusted EBITDA margin declined 77 basis points to 21.1%, primarily due to an increasing, structural reliance on paid digital search leads (such as Google Local Services) as organic phone book and legacy marketing fade into obsolescence. The cost of customer acquisition in emergency home services is structurally inflating as digital advertising platforms extract maximum rent from local service providers. Paid search leads ballooned from 44% to 59% of total intake over the last 18 months, representing a permanent shift in the expense profile.
Judgment:Negative — This is a structural headwind. While management is attempting to offset this decay by accelerating the closure rate of high-ticket commercial B2B contracts, the era of “free” organic lead generation is over, effectively capping peak plumbing margins near current levels.
Q4: How Severe is the Ongoing Medicare Cap Regulatory Threat to VITAS?
Analysis: Medicare implements a hard aggregate cap on the amount a hospice can bill annually to prevent fraudulent over-treatment and excessive lengths of stay. In Q2 2025, VITAS suffered a brutal $16.4 million cap limitation charge. However, in Q2 2026, the company successfully reengineered its patient mix and admission velocities—specifically increasing hospital-based admissions to 42.9% in the critical Florida market—reducing the cap penalty to a negligible $0.5 million and lowering full-year 2026 penalty expectations to just $7.0 million.
Judgment:Positive — Management has decisively proven its ability to operationally maneuver around localized geographic Medicare cap constraints through strategic admission adjustments, de-risking the regulatory overhang that plagued the stock last year.
Q5: Does the Barington Capital Activist Campaign Have Teeth?
Analysis: Barington holds a relatively small 0.43% stake but leverages significant media presence and undeniable industry logic to pressure the board. Their demands—cutting personal aircraft use, refreshing the board with private equity veterans like Chan Galbato, and demanding a comprehensive strategic review—resonate strongly with institutional shareholders frustrated by governance complacency and the persistent conglomerate discount.
Judgment:Positive — Even if a full spin-off is not immediately achieved due to tax friction, activist involvement forces management to remain hyper-disciplined regarding corporate costs and capital allocation, heavily insulating the stock’s downside.
Q6: Can Chemed Sustain Its Aggressive Share Repurchase Velocity?
Analysis: Retiring 10.5% of the total float in a single trailing 12-month period is a monumental feat of capital return. Chemed funded this organically via $173+ million in operating cash flow and a new $450 million revolving credit facility, which currently holds $262.7 million in undrawn capacity. This financial engineering leverages the cash generation of both businesses to continually shrink the equity base.
Judgment:Positive — With interest coverage exceeding 111x and minimal long-term debt, Chemed possesses near-infinite flexibility to draw cheap debt to supplement organic cash flow, guaranteeing the buyback engine will persist uninterrupted for the foreseeable future.
Q7: Are Roto-Rooter Franchise Acquisitions a Viable Growth Engine?
Analysis: Chemed actively purchases independent Roto-Rooter franchises, such as the recent $20.6 million Texas/California deals, converting them into company-owned branches. This strategy is highly accretive, eliminating franchise fee friction and allowing the parent company to capture the full, unadulterated margin profile of established, locally dominant operators without the risk of entering entirely new markets.
Judgment:Positive — This represents the ultimate low-risk capital deployment strategy; it guarantees predictable returns on capital without the integration risks typical of cross-industry M&A, slowly converting the entire North American network into a high-margin corporate asset.
Q8: Will the FY 2027 Hospice Wage Index Update Stifle VITAS Profitability?
Analysis: CMS recently finalized a 2.3% rate increase for FY 2027, establishing the aggregate payment cap at $36,174.75. While optically positive, a 2.3% top-line bump lags significantly behind national wage inflation for highly skilled registered nurses and healthcare professionals, threatening to compress gross margins if operational efficiencies fail to bridge the widening gap.
Judgment:Negative — The structural mismatch between government-dictated pricing updates and real-world labor inflation forces VITAS to rely entirely on volume growth (Average Daily Census) rather than pricing power to drive EPS expansion.
Q9: Does the Surge in VITAS Hospital Admissions Alter the Margin Profile?
Analysis: In Q2 2026, hospital additions accounted for nearly 43% of total admissions in critical markets like Florida. Hospital-based admissions typically represent patients entering hospice later in their disease progression, leading to shorter overall lengths of stay but higher initial acuity and related nursing costs.
Judgment:Neutral — While shorter lengths of stay challenge the efficiency of the traditional hospice model, they are absolutely essential for mitigating Medicare Cap penalties by naturally regulating billing limits, representing a necessary operational trade-off that management is executing perfectly.
Q10: Are Insider Sales by Chemed Executives a Warning Sign?
Analysis: CEO Kevin McNamara’s recent $1.1 million stock sale, alongside similar director sales, occurred at the upper bound of the stock’s 52-week range near $540. In a vacuum, this suggests insiders view the valuation as stretched. However, these sales generally follow options exercises, which are routine, mechanical liquidity events for long-tenured executives attempting to diversify their personal wealth.
Judgment:Neutral — The complete lack of cluster buying is the primary takeaway; management is not aggressively acquiring shares personally at 27x earnings, aligning perfectly with the conclusion that the stock is currently fairly-to-overvalued, but not signaling an imminent fundamental collapse.